Results 221 to 230 of about 55,025 (289)

Enhancing Veliparib PARP1 inhibitor stability against UVC degradation <i>via</i> DPPG liposome encapsulation. [PDF]

RSC Adv
Conceição CJF, Moe E, Ribeiro PA, Raposo M.   +3 more
europepmc   +1 more source

Roles of ADP-Ribosyltransferases in Cancer. [PDF]

Oncol Res
Veilleux M, Nguyen A, Cao C, Shi Y.
europepmc   +1 more source

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. [PDF]

Cancer Res
Herzog SK, Stevens JH, Gu G, Grimm SL, Cardoza K, Hawkins AGM, Lin H, Ramos D, Beyer AR, Edwards DG, Dustin D, Yang HJ, Liang N, Khan AF, Bawa-Khalfe T, McGrail DJ, Lin SY, Coarfa C, Fuqua SAW.   +18 more
europepmc   +1 more source

PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation. [PDF]

Sci Adv
Zhu X, Huo Q, Jin L, Du J, Yu J, Wang H, Wu N, Li Y, Rui Y, Zhao C, Zhou J, Zhang Y, Li H, Lin J, Zheng C, Li W.   +15 more
europepmc   +1 more source

Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5<i>H</i>-pyrrolo[3,4-<i>d</i>]pyrimidine-based PARP1/ATR dual inhibitors. [PDF]

J Enzyme Inhib Med Chem
He ML, Wang ZH, Yao X, Ye LL, Du BQ, Wang CC, Chen YH, Wang XX, Luo H, Gao Y, Ye XY.   +10 more
europepmc   +1 more source

Machine learning and free energy clustering reveal PAH protein binding linked to AD risk. [PDF]

iScience
Chen C, He Y, Ni Y, Song D, Chu M, Zhang W.   +5 more
europepmc   +1 more source

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. [PDF]

Cell Rep Med
Le BV, Vekariya U, Toma MM, Nieborowska-Skorska M, Caron MC, Gozdecka M, Haydar Z, Walsh M, Ghosh J, Vaughan-Williams E, Podszywalow-Bartnicka P, Kukuyan AM, Ziolkowska S, Atkins J, Hadzijusufovic E, Chandramouly G, Nejati R, Piwocka K, Pomerantz R, Vassiliou GS, Huntly BJP, Valent P, Wasik M, Bellacosa A, Masson JY, Gupta GP, Challen GA, Skorski T.   +27 more
europepmc   +1 more source

PJ34 Prevents Trauma-Induced Heterotopic Ossification without Adverse Bone Healing: An in vivo and in vitro Investigation. [PDF]

Drug Des Devel Ther
Zhang W, Hou J, Feng H, Zhu J, Liang Y, Mu W, Xu P, Qian Y, Jiang S.   +8 more
europepmc   +1 more source

Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective. [PDF]

Biomark Res
Xiang J, Li J, Guo Z, Wu J, Ma D, Xu H, Shang T, Pu P, Cong L, Zhou R, Wang X, Yu Y, Liu J.   +12 more
europepmc   +1 more source

Targeting m⁶A RNA methylation to sensitize cancer cells to DNA-damaging therapies. [PDF]

Discov Oncol
Cesaro B, Venezia S, Tarullo M, Piscopo F, Fatica A.   +4 more
europepmc   +1 more source